Financial Performance - Net profit attributable to shareholders was ¥135,967,095.99, representing a year-on-year increase of 22.63%[4] - Operating revenue for the period was ¥760,873,089.31, reflecting a growth of 6.98% compared to the same period last year[4] - Basic and diluted earnings per share were both ¥0.23, up 21.05% from the previous year[4] - Total operating revenue for Q1 2020 was ¥760,873,089.31, an increase of 6.9% compared to ¥711,227,260.18 in Q1 2019[19] - Net profit for Q1 2020 reached ¥135,967,095.99, representing a 22.6% increase from ¥110,877,096.50 in Q1 2019[19] - Operating profit for Q1 2020 was CNY 146,519,749.43, a rise of 32.3% from CNY 110,801,874.34 in Q1 2019[21] - The company achieved a net profit from continuing operations of CNY 121,653,717.81 in Q1 2020, reflecting a strong performance compared to the previous year[21] Assets and Liabilities - Total assets at the end of the reporting period reached ¥5,236,462,136.59, an increase of 1.28% compared to the end of the previous year[4] - The company's total equity increased to CNY 4,004,710,883.08 from CNY 3,867,778,257.07, marking a growth of about 3.67%[14] - Total current liabilities decreased to CNY 1,183,058,106.87 from CNY 1,252,787,393.35, a reduction of approximately 5.55%[13] - The total liabilities decreased to CNY 1,231,751,253.51 from CNY 1,302,497,280.42, reflecting a reduction of approximately 5.45%[14] - The non-current assets totaled CNY 2,248,209,066.20, up from CNY 2,167,028,133.48, representing an increase of approximately 3.74%[13] Cash Flow - The net cash flow from operating activities was ¥59,751,196.86, a decrease of 5.21% year-on-year[4] - The net cash flow from operating activities for Q1 2020 was CNY 59,751,196.86, down from CNY 63,037,773.00 in the same period last year, indicating a decrease of about 5.4%[22] - Cash inflows from investment activities totaled CNY 311,839,719.69 in Q1 2020, a decrease from CNY 799,535,479.79 in Q1 2019, representing a decline of about 61%[23] - The net cash flow from investment activities was -CNY 178,825,779.90 in Q1 2020, compared to 235,283,957.83 in Q1 2019, indicating a significant decline[23] - The net cash flow from financing activities was CNY -112,167,562.47 in Q1 2020, compared to CNY 293,181,136.31 in Q1 2019, indicating a substantial decrease[23] Expenses - Total operating costs for Q1 2020 were ¥594,675,995.39, up from ¥579,307,551.16 in Q1 2019, reflecting a rise of 2.5%[19] - The company reported a financial expense of CNY -11,967,847.10 in Q1 2020, compared to a financial income of CNY 4,356,659.87 in Q1 2019[21] - Research and development expenses for Q1 2020 were ¥26,906,819.38, slightly down from ¥27,108,753.43 in Q1 2019[19] - The tax expenses for Q1 2020 amounted to CNY 21,318,516.37, compared to CNY 16,560,216.81 in Q1 2019[21] Other Financial Metrics - The weighted average return on equity increased by 0.35 percentage points to 3.45%[4] - Other receivables increased by 53.76% compared to the beginning of the year, mainly due to land compensation payments[11] - Financial expenses decreased by 330.35% year-on-year, primarily due to increased exchange gains[11] - Investment income decreased by 84.16% compared to the same period last year, mainly due to reduced returns from bank principal-protected financial products[11] - The company's cash and cash equivalents decreased to CNY 907,677,492.17 from CNY 1,059,912,920.57, a decline of about 14.3%[12] - The company's cash and cash equivalents at the end of Q1 2020 stood at CNY 811,162,318.74, down from CNY 967,293,990.94 at the end of Q1 2019, reflecting a decrease of about 16%[23]
山东药玻(600529) - 2020 Q1 - 季度财报